top of page
Recent News

July 20, 2021

Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP

June 30, 2021


Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase


June 15, 2021


Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties

June 9, 2021


Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platfomr



May 18, 2021


Oncology Pharma, Inc. Is Pursuing the Development of its Small Molecule Drug for the Treatment of Colon Cancer



May 7, 2021

Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer

April 21, 2021

Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform


April 14, 2021


Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology


April 7, 2021


Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer


March 31, 2021


Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities


March 16, 2021


Oncology Pharma Reveals Strategic Plans for Company Growth and Focus


March 10, 2021


Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy


March 4, 2021


Oncology Pharma Moves to Fund Lead Drug Formulation & IND-Enabling Studies



February 26, 2021

Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent

February 22, 2021

Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology

February 16, 2021

Oncology Pharma is Pleased to Welcome New Chairman to its Scientific Advisory Board


February 9, 2021

Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for its Connect2Med Clinical Trials Platform



February 3, 2021

Oncology Pharma Extends its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology

January 28, 2021

Oncology Pharma Announces the Appointment of New Chief Financial Officer


August 27, 2020

Oncology Pharma Announces Extension of Letter of Intent with Kalos Therapeutics, Retained an Interim CEO and Approval of Reverse Stock Split



April 21, 2020

Oncology Pharma Licensor and Co-Development Partner, Kalos Therapeutics, Announces Progress in Covid-19 Preventative & Therapeutic Approaches

April 6, 2020

Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19

March 11, 2020


Oncology Pharma Continues Licensing Agreement with NanoSmart



January 28, 2020

Oncology Pharma, Inc. Narrows Focus on Funding Efforts



December 26, 2019

Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Investment Partners, Ltd.

bottom of page